发明名称 |
Treatment of circadian rhythm disorders |
摘要 |
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
申请公布号 |
US8785492(B2) |
申请公布日期 |
2014.07.22 |
申请号 |
US201313751011 |
申请日期 |
2013.01.25 |
申请人 |
Vanda Pharmaceuticals Inc. |
发明人 |
Dressman Marlene Michelle;Feeney John Joseph;Licamele Louis William;Polymeropoulos Mihael H. |
分类号 |
A61K31/343;A61K31/00;G01N33/68 |
主分类号 |
A61K31/343 |
代理机构 |
Hoffman Warnick LLC |
代理人 |
Swinton, Jr. Stephen F.;Hoffman Warnick LLC |
主权项 |
1. A method of entraining a patient suffering from Non-24 to a 24 hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours, and maintaining said 24 hour sleep-wake cycle said method comprising: treating the patient by orally administering to the patient 20 mg of tasimelteon once daily before a target bedtime. |
地址 |
Washington DC US |